FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 37 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy... October 9, 2020 ESMO Highlights Key Issues for Patients with Cancer and Their Carers... May 27, 2025 Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... July 8, 2021 Moxetumomab Approved by FDA for Hairy Cell Leukemia September 14, 2018 Load more HOT NEWS Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... Oncotype DX Breast Cancer Test May Be Less Accurate for Black... Fake Amazon Delivery Driver Attempts to Steal Elderly Woman’s Cancer Drugs
